tiprankstipranks
Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
Australian Market

Tryptamine Therapeutics (TYP) Income Statement

Compare
11 Followers

Tryptamine Therapeutics Income Statement

Last quarter (Q4 2022), Tryptamine Therapeutics's total revenue was $―, a decrease of ― from previous quarter. In Q4, Tryptamine Therapeutics's net income was $―. See Tryptamine Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22Jun 21Jun 20Jun 19
Total Revenue
$ ―$ ―$ ―$ ―
Gross Profit
$ 99.73K$ ―$ 2.62M$ ―
Operating Expenses
$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ 1.73M$ 1.01M$ 382.42K$ ―
EBITDA
$ -8.27M$ -11.66M$ -7.62M$ -2.31M
Operating Income
$ -14.11M$ -12.67M$ -8.00M$ -2.31M
Other Income/Expenses
$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―
Net Income
$ -10.08M$ -8.47M$ -5.28M$ -2.28M
Per Share Metrics
$ ―$ ―$ ―$ ―
Basic EPS
$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding (Diluted)
Currency in USD

Tryptamine Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis